

2018 OPA Annual Conference Learning Objectives

ACPE #0129-0000-18-015-L04-P

Improving Patient Outcomes and Expanding Pharmacy Practice through Population Health Management

Kelli D. Barnes, PharmD, BCACP, Clinical Pharmacist, The OSU General Internal Medicine Clinics

At the completion of this activity, the participant will be able to:

1. describe the emergence of population health management;
2. outline successful pharmacist-led population health management interventions;
3. summarize lessons learned while designing a population health management focus in primary care; and
4. describe opportunities to advance pharmacy practice through population health management and innovative payment models.

ACPE #0129-0000-18-016-L04-P

Tips for Effective Precepting: Expectations, Evaluation & Feedback

Experiential Education Directors, Ohio Colleges of Pharmacy

At the completion of this activity, the participant will be able to:

1. describe the value of setting expectations in experiential education;
2. compare various feedback types and discuss the pros and cons of each;
3. identify barriers to providing useful feedback to students and residents; and
4. rate a student's ability to self-assess and use techniques to improve their self-assessment skills.

ACPE #0129-0000-18-017-L01-P

Help or Harm: A Look at Psychotropic Medication Use in Adolescents

Sara Dugan, PharmD, BCPP, BCPS, Associate Professor, Northeast Ohio Medical University

At the completion of this activity, the participant will be able to:

1. identify the most prevalent mental health conditions found in adolescent patients;
2. assess the efficacy of psychotropic medications in the treatment of common mental health conditions in adolescent patients;
3. evaluate the safety profiles of psychotropic medications used in the treatment of adolescent patients; and
4. outline pharmacist interventions, including psychotropic medication monitoring parameters and counseling points, for adolescent patients with mental health conditions and their families/caregivers.

ACPE #0129-0000-18-018-L04-P

Opioid Crisis: How To Use GenerationRx To Help

Justin Friesner, R.Ph., PharmD, Pharmacy Business Specialist, The Kroger Company

At the completion of this activity, the participant will be able to:

1. list three potential audiences for the GenerationRx program;
2. identify how to access the GenerationRx materials; and
3. describe the requirement for public educators to teach about opiates and other drugs, and how pharmacists can serve in teaching.

ACPE #0129-0000-18-019-L01-P

What's Going Down with Hypertension?!

Vincent F. Mauro, RPh, PharmD, FCCP, Professor of Clinical Pharmacy

The University of Toledo College of Pharmacy and Pharmaceutical Sciences

At the completion of this activity, the participant will be able to:

1. identify what hypertension is in 2017;
2. define the goals of treating hypertension in 2017;
3. describe 2017 approaches to treating hypertension; and
4. discuss important clinical perspectives of commonly-used antihypertensive medications

ACPE #0129-0000-18-020-L01-P

2018 OTC and Self-Care Challenge

Moderators: Brigid Groves, R.Ph., PharmD, MS, Pharmacist Care Services Coordinator, Kroger; and

Justin Brown, R.Ph., PharmD, Staff Pharmacist, WalMart

At the completion of this activity, the participant will be able to:

1. discuss current topics related to nonprescription medications;
2. describe appropriate nonprescription treatment options for common self-care conditions;
3. identify the rationale for the selection of a particular product for a described self-care condition;
4. describe at least two interactions between over-the-counter and prescription medications; and
5. identify key counseling points for OTC medications.

ACPE #0129-0000-18-021-L01-P

Addressing Insomnia in the Community Pharmacy Setting

Leandro A. Llambí, PharmD, Pharmacy Manager and Patient Care Pharmacist, Kroger Pharmacy

At the completion of this activity, the participant will be able to:

1. describe both short and long-term health consequences of poor sleep;
2. identify patients who may be at risk for complications from insomnia;
3. assess patients for quality of sleep;
4. recommend over-the-counter options for treating insomnia;
5. design an appropriate therapeutic regimen to improve sleep based upon patient-specific information; and
6. explain how to counsel patients on non-pharmacologic techniques for improving sleep.

ACPE #0129-0000-18-022-L04-P

Does the CFO Have a Drug Problem?

Scott McGohan, Chief Executive Officer, McGohan Brabender

At the completion of this activity, the participant will be able to:

1. recognize the role of a chief financial officer (CFO) in prescription drug cost control for self-insured employers;
2. identify ways for employers to rein in healthcare costs; and
3. discuss opportunities for pharmacists to evolve their practice models to help address the needs of employers.

ACPE #0129-0000-18-023-L04-P

Ohio Research Forum 2018

Moderator: Timothy R. Ulbrich, PharmD, Associate Dean, Workforce Development and Practice Advancement, NEOMED

At the completion of this activity, the participant will be able to:

1. identify research projects being conducted by pharmacists, student pharmacists and faculty in Ohio; and
2. describe the impact these research projects have on the practice of pharmacy, economic/social/administrative areas within the profession and/or the design of pharmacy education.

ACPE #0129-0000-18-024-L04-P

Billing Clinical Services in the Outpatient Setting

Michael J. Rush, PharmD, BCACP, CDE, TTS

*Assistant Clinical Professor of Pharmacy Practice, Ohio Northern University; and
Chuck Riepenhoff, R.Ph., CDE, Clinical Pharmacist, ProMedica Pharmacy Counter*

At the completion of this activity, the participant will be able to:

1. discuss how billing codes can be applied to services provided by a pharmacist;
2. explain current and emerging reimbursement options for cognitive services; and
3. discuss different MTM programs and the associated outcomes.

ACPE #0129-0000-18-025-L04-P

Pharmacy Workforce Trends

Donald L. Bennett, R.Ph., MBA, Clinical Assistant Professor, OSU College of Pharmacy

At the completion of this activity, the participant will be able to:

1. discuss the recent trends in the supply of pharmacists;
2. discuss the current and future projected changes in the demand for pharmacists;

3. describe the concepts of the Pharmacist Demand Index (PDI) in tracking the demand for pharmacists by state, region, and general practice setting; and
4. discuss strategies for pharmacists to increase our impact on health and wellness of patients in the changing U.S. healthcare system.

ACPE #0129-0000-18-026-L04-P

Suddenly In-Charge: How to Be an Effective Young Pharmacy Leader in the Workplace

Moderator: Jennifer Sabatino, PharmD, R.Ph., BCACP, Clinical Pharmacist at OSU General Internal Medicine; Panelists: Shannon Link, PharmD, R.Ph., Clinical Coordinator for Schwieterman Pharmacies; Michelle Maguire, PharmD, R.Ph., BCACP, Clinical Pharmacist at Southeast, Inc. Healthcare Services; Ashley Neidig, PharmD, R.Ph., Walmart Pharmacy Manager; Patrick Owcarz, PharmD, R.Ph., Director of Pharmacy at Berger Health System; Derek Singrey, PharmD, R.Ph., Kroger Pharmacy Leader; Robert Logan Yoho, PharmD, R.Ph., BCACP, Director of Pharmacy at Hopewell Health Centers

At the completion of this activity, the participant will be able to:

1. recognize and prepare for challenges he/she may face as a new practitioner in a leadership role; and
2. identify tools to help him/her succeed as a young pharmacy leader.

ACPE #0129-0000-18-027-L04-P

Ohio Innovative Practice Forum 2018

Jennifer Rodis, PharmD, BCPS, Assistant Dean for Outreach and Engagement, OSU College of Pharmacy; Timothy R. Ulbrich, PharmD, Associate Dean, Workforce Development and Practice Advancement, NEOMED

At the completion of this activity, the participant will be able to:

1. describe innovative pharmacy practice models in Ohio;
2. identify how individual pharmacy practices and practitioners are expanding patient care services;
3. describe the successes and challenges of these programs including their financial viability and impact on outcome measures; and
4. apply these ideas, opportunities, and resources to enhance his/her own pharmacy practice.

ACPE #0129-0000-18-028-L01-P

Unrelenting, Uncontrolled, and Unacceptable – How to Undo Migraine Headache Pain

Mary C. Borovicka, PharmD, BCPS, BCPP

Associate Professor, University of Toledo College of Pharmacy and Pharmaceutical Sciences; and Clinical Pharmacist- Psychiatry, MetroHealth Medical Center, Cleveland

At the completion of this activity, the participant will be able to:

1. identify and describe the different phases of a migraine attack;
2. describe the diagnostic criteria for migraine with aura and migraine without aura as defined by the International Headache Society (IHS);
3. identify the symptoms that accompany migraine headaches;
4. discuss common migraine triggers and strategies to address these triggers;
5. given a case, select an appropriate medication for an acute migraine attack or for prevention of migraine headaches based on AAN/AHS treatment guidelines, duration of therapy, potential side effects, drug-drug interactions, and patient comorbidities; and
6. discuss the management of medication overuse headaches and chronic migraine.

ACPE #0129-0000-18-029-L01-P

Medical Marijuana - Sorting Through the Haze

Justin Kullgren, PharmD, CPE,

Palliative Medicine Clinical Pharmacy Specialist, OSU Wexner Medical Center

At the completion of this activity, the participant will be able to:

1. explain the Ohio medical marijuana law;
2. discuss relevant pharmacology of medical marijuana;
3. review evidence of medical marijuana for Ohio's approved uses; and
4. discuss clinical implications of patients using medical marijuana.

ACPE #0129-0000-18-030-L05-P

Being Human: Medication Errors and the Human in the Middle

*Mark Thomas, M.S., R.Ph., Chief Pharmacy Director and Medication Safety Officer
Cincinnati Children's Hospital Medical Center*

At the completion of this activity, the participant will be able to:

1. identify three human performance issues that contribute to medication errors;
2. describe specific behavioral and medication safety tools to help prevent errors; and
3. describe recent trends in medication errors.

ACPE #0129-0000-18-031-L03-P

Pharmacy Law Update, Spring 2018

Sheri Zapadka, R.Ph., Compliance Specialist; State of Ohio Board of Pharmacy

At the completion of this activity, the participant will be able to:

1. identify recent changes in state and federal laws and rules which impact pharmacy practice;
2. describe the effect of recent changes in laws and rules on his/her specific practice of pharmacy; and
3. review commonly asked questions about existing pharmacy laws and rules.

ACPE #0129-0000-18-032-L04-P

Don't Be an Audit Target in 2018

Mark Jacobs, R.Ph., FASCP, Vice President of Operations, PAAS National®

At the completion of this activity, the participant will be able to:

1. define common audit requirements;
2. describe what pharmacy auditors look for; and
3. identify strategies to avoid payment recovery.

ACPE #0129-0000-18-033-L01-P

Advances in Diabetes Management: An Update on Insulin Pumps, Innovative Technology and Newer Therapies

Christopher D. Westrick, PharmD, BCACP, CDE, Specialty Practice Pharmacist, OSU Wexner Medical Center Department of Family Medicine and OSU College of Nursing Total Health and Wellness Clinic

At the completion of this activity, the participant will be able to:

1. discuss the advantages and disadvantages of insulin pump therapy;
2. compare and contrast the currently available insulin pumps;
3. identify new technology in the management of diabetes; and
4. describe new therapies for diabetes management.

ACPE #0129-0000-18-034-L04-P

Utilizing PBMs to Implement Innovation in the Community Pharmacy: A Panel Discussion

Moderator: Marc A. Sweeney, PharmD, Dean, Cedarville University School of Pharmacy

At the completion of this activity, the participant will be able to:

1. discuss the historical, current and future roles of Pharmacy Benefit Managers (PBMs).;
2. describe various community pharmacy models that utilize a novel PBM approach; and
3. identify opportunities for pharmacists to expand revenue streams through unique PBM models.

ACPE #0129-0000-18-035-L01-P

Hepatitis C Treatment Updates

Arpi H. Roach, PharmD, CDE

Clinical Pharmacy Specialist, Chalmers P. Wylie VA Ambulatory Clinic, Columbus

At the completion of this activity, the participant will be able to:

1. discuss the epidemiology and prevalence of Hepatitis C;
2. outline how Hepatitis C is transmitted;
3. explain the screening recommendations for Hepatitis C;
4. identify tests needed to diagnose Hepatitis C;
5. differentiate between acute and chronic Hepatitis C infections;
6. identify the goal of Hepatitis C treatment;

7. describe the pathophysiology of the Hepatitis C Virus and how medications are targeted to help cure Hepatitis C infection;
8. discuss tests and assessments that are needed prior to Hepatitis C treatment;
9. outline available treatment regimens for Hepatitis C Virus and recognize important differences between direct acting antivirals;
10. choose a treatment regimen based on patient characteristics; and
11. describe current barriers to treatment.

ACPE #0129-0000-18-036-L01-P

OTC/Self-care Update: New Products, New Literature, New Cases

Daniel L. Krinsky, M.S., R.Ph., Associate Professor, Department of Pharmacy Practice, Northeast Ohio Medical University

At the completion of this activity, the participant will be able to:

1. list new over-the-counter products that became available in 2017;
2. describe at least one new treatment for head lice and one new device for home ovulation testing;
3. summarize new evidence describing the potential risks associated with proton pump inhibitors (PPIs);
4. utilizing the studies that were reviewed, describe the significance of NSAIDs in increasing the risk of myocardial infarction; and
5. given a patient case, apply information from the studies discussed to his/her decision-making process and determine the best self-care option for the patient.

ACPE #0129-0000-18-037-L05-P

Implementing Just Culture in the Pharmacy

Amber D. Hartman, PharmD

Medication Safety Pharmacist, OSU Wexner Medical Center

At the completion of this activity, the participant will be able to:

1. define “Just culture” and contrast this model with outcome-based models;
2. differentiate between human error, at-risk behavior, and reckless behavior; and
3. determine an appropriate response to an error based on the Just Culture model when given a patient case scenario.

ACPE #0129-0000-18-038-L04-P

Innovative Pharmacy Business Plan Competition 2018

Finalist teams and panel of judges TBA

At the completion of this activity, the participant will be able to:

1. identify essential components of a business plan, including mission statement, description of business, loan request, marketing plan and financial reports;
2. explain the importance of effective visual aids and nonverbal communication during presentation of a business plan; and
3. recognize how enthusiasm, professionalism and completeness can impact the effectiveness of a business plan presentation.

ACPE #0129-0000-18-039-L04-P

Development of a Medication Therapy/Chronic Disease Management Clinic in a Small Community Hospital to Optimize Clinical Outcomes and Reduce Hospital Readmission Rates

Britt A. Cummins, M.S., R.Ph., Director of Pharmacy, Memorial Hospital, Marysville, OH

At the completion of this activity, the participant will be able to:

1. describe a medication therapy/disease management model that is designed to provide a comprehensive approach to medication therapy and chronic disease management through a combination of transition of care and long term longitudinal strategies;
2. describe the clinical pharmacist-midlevel provider staffing model utilized to provide transition of care and chronic medication/disease management services; and

3. describe the financial and clinical outcome measures utilized to evaluate the effectiveness of outpatient Medication Therapy/Chronic Disease Management clinics.

ACPE #0129-0000-18-040-L01-P

Pharmacist Implementation of an Opioid Antagonist Addiction Treatment Clinic in an Outpatient Setting

Emily Blaiklock, PharmD, Specialty Pharmacist, St. Matthews Community Pharmacy, Louisville, KY

At the completion of this activity, the participant will be able to:

1. compare and contrast the most common types of medications currently available for opioid use disorder;
2. describe the workflow of an opioid antagonist addiction treatment clinic run by a pharmacist in an outpatient setting;
3. discuss opportunities for reimbursement for a pharmacist's time invested in the successful administration of an opioid antagonist;
4. identify common barriers associated with opening and operating an opioid antagonist addiction treatment center; and
5. explain the pharmacist's role in the opioid addiction treatment continuum and the greater good of public health.

ACPE #0129-0000-18-041-L01-P

Functional Medicine: It All Starts in the Gut!

Melody L. Hartzler, PharmD, AE-C, BCACP, BC-ADM; Associate Professor, Cedarville University School of Pharmacy and Clinical Pharmacist, Western Medicine Family Physicians, Fairborn, Ohio; and Lauren Castle, PharmD, Market Health and Wellness Director, Walmart Stores Inc. and Founder, Functional Medicine Pharmacists Alliance

At the completion of this activity, the participant will be able to:

1. describe the impact of altered gut microbiota and gut inflammation on GI disorders and overall health;
2. recognize environmental factors that influence gut microbiota;
3. describe Small Intestinal Bacterial/Fungal Overgrowth (SIBO/SIFO);
4. select pharmaceutical and non-pharmaceutical supplements options to address healing the gut and re-establishing healthy gut flora;
5. compare and contrast dietary modifications for patients with GI disorders; and
6. discuss integrative treatment options for prevalent GI disorders.

ACPE #0129-0000-18-042-L01-P

Kids Get Arthritis Too, Don't Let it Bankrupt You

Kelly Wise, PharmD, BCACP; Kasandra Chambers, PharmD, MBA; and Megan McNicol, PharmD; Nationwide Children's Hospital, Columbus

At the completion of this activity, the participant will be able to:

1. review the presentation and classification of juvenile idiopathic arthritis (JIA);
2. describe treatment strategies for JIA;
3. discuss the specialty pharmacy environment; and
4. explain the role of a pharmacist within a specialty clinic.

ACPE #0129-0000-18-043-L01-P

Clinical Case Studies From an Outpatient Medication Therapy/Chronic Disease Management Clinic Based in a Small Community Hospital Setting

Craig Baker, PharmD, Clinical Pharmacist

Medication Therapies Clinic, Memorial Hospital, Marysville, OH

At the completion of this activity, the participant will be able to:

1. list and describe common patient clinical and medication issues that can often occur during transitions of care between hospital to home and hospital to other healthcare facilities;
2. list and describe opportunities that are available to pharmacists to optimize care and clinical outcomes during care transitions;

3. describe a pharmacist-midlevel provider model for improving transitions of care and reducing hospital readmission rates for patients with common chronic diseases;
4. list and describe clinical strategies and interventions utilized by a heart failure clinic to optimize medication management, lifestyle challenges, and patient clinical outcomes;
5. describe clinical and financial outcomes for a pharmacist-midlevel provider based Heart Failure Clinic;
6. list and describe clinical strategies and interventions utilized by a COPD clinic to optimize medication management, lifestyle challenges, and patient clinical outcomes; and
7. list and describe clinical and financial outcomes for a pharmacist-midlevel provider based COPD Clinic.

ACPE #0129-0000-18-044-L01-P

How to Say No: Rational Discontinuation of Opioid Analgesics

Phyllis Grauer, R.Ph., PharmD, BCGP, CPE, Palliative Care, Pain and Substance Abuse Clinical Consultant

At the completion of this activity, the participant will be able to:

1. list factors which influence the appropriateness for opioid discontinuation;
2. describe tapering methods for discontinuing opioids safely; and
3. discuss communication and educational strategies for successfully supporting patients and prescribers when discontinuing opioids.

ACPE #0129-0000-18-045-L04-P

Expanding Pharmacy Services to Improve Public Health

Natalie DiPietro Mager, PharmD, MPH, Associate Professor of Pharmacy Practice, Ohio Northern University Raabe College of Pharmacy

At the completion of this activity, the participant will be able to:

1. list the public health priorities from Ohio's Health Improvement Plan;
2. describe roles for pharmacists to improve public health; and
3. explain how pharmacists can improve public health through clinical-community linkages and provision of clinical preventive services.

ACPE #0129-0000-18-046-L04-P

Patient-Centered Medical Home Model of Care: Expanding Pharmacy Services

Michelle Cudnik, PharmD, BCACP, Clinical Lead Pharmacist, Ambulatory Care and PGY2 Ambulatory Care Residency Program Director, Summa Health

At the completion of this activity, the participant will be able to:

1. define an integrated model of care and describe the Patient-Centered Medical Home standard;
2. describe how layered learning can help with expanding pharmacy services;
3. discuss key stakeholders involvement with pharmacy services; and
4. evaluate quality metrics and how they can help promote and sustain your pharmacy service.

ACPE #0129-0000-18-047-L01-P

New Drug Update 2018

Karen L. Kier, PhD, M.Sc., R.Ph., Professor of Clinical Pharmacy Practice, Director of Assessment, Director of Drug and Health Information, Ohio Northern University College of Pharmacy

At the completion of this activity, the participant will be able to:

1. describe the pharmacology and therapeutics of the drugs presented that were released to market within the past year;
2. state the indications and clinical applications of the medications presented;
3. identify the most common adverse effects, toxicities, and significant drug-drug interactions reported with these medications; and
4. explain important patient counseling information on these medications.

ACPE #0129-0000-18-048-L04-P

Legislative Update 2018

Ernest Boyd, PharmD (Hon), CAE, and Antonio Ciaccia, OPA Lobbyists

At the completion of this activity, the participant will be able to:

1. describe recent legislative and regulatory changes that impact the practice of pharmacy;
2. explain the progress of pending and future advocacy initiatives, including epinephrine accessibility, Medicaid reimbursement, provider status and PBM clawbacks; and
3. discuss OPA's legislative agenda for 2018 and what it could mean for pharmacy practice.

ACPE #0129-0000-18-049-L04-P

Ethics in Pharmacy Practice: Case Study Debates 2018

Dennis M. Sullivan, MD, MA (Ethics), Director, Center for Bioethics, and Professor of Pharmacy Practice; and PharmD Candidates Abigail Savino, Brandon Spears, Casey Nelson, and Caleb Tang, Cedarville University

At the completion of this activity, the participant will be able to:

1. describe the competing ethical duties that inform the use of naloxone in overdose patients; and
2. recognize the scientific, legal, and ethical challenges in the regulation of medical marijuana.

ACPE #0129-0000-18-050-L04-P

Motivational Interviewing to Enhance Pharmacy Patient Outcomes

Russell E. Spieth, PhD, CRC, Senior Consultant/Trainer in Motivational Interviewing Department of Psychiatry, NEOMED; and Jaclyn Boyle, PharmD, MS, MBA, BCACP, BCPS, Assistant Professor for Community Pharmacy Innovation, NEOMED

At the completion of this activity, the participant will be able to:

1. discuss how motivational interviewing (MI) can improve patient adherence and health outcomes;
2. describe the dimensions of the MI spirit; and
3. demonstrate use of MI skills to address patients in pre-contemplation, contemplation and preparation phases of the transtheoretical model of change.

ACPE #0129-0000-18-051-L07-P

Selecting Components for Compounding

Richard Dilzer, R.Ph., FACA, FIACP, Director, Pharmacy Technical Services, Spectrum Pharmacy Products

At the completion of this activity, the participant will be able to:

1. review the process of component selection from USP General Compounding chapters standards;
2. identify the factors of chemicals that can affect preparation accuracy and potency;
3. explain the values reported in the certificate of analysis and how to adjust for them; and
4. discuss the importance of documentation of component quality and conformance.

ACPE #0129-0000-18-052-L06-P

Immunization Update 2018

Donald L. Bennett, R.Ph., MBA, Clinical Assistant Professor, OSU College of Pharmacy

At the completion of this activity, the participant will be able to:

1. discuss the CDC identified trends in vaccine preventable disease prevalence;
2. describe the recent changes in recommendations from the CDC Advisory Committee on Immunization Practices; and
3. discuss the impact of the 2017-2018 influenza season.